U.S. flag

An official website of the United States government

NM_000059.4(BRCA2):c.7051G>A (p.Ala2351Thr) AND not specified

Germline classification:
Conflicting classifications of pathogenicity (2 submissions)
Last evaluated:
Sep 23, 2024
Review status:
criteria provided, conflicting classifications
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000212257.17

Allele description [Variation Report for NM_000059.4(BRCA2):c.7051G>A (p.Ala2351Thr)]

NM_000059.4(BRCA2):c.7051G>A (p.Ala2351Thr)

Gene:
BRCA2:BRCA2 DNA repair associated [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
13q13.1
Genomic location:
Preferred name:
NM_000059.4(BRCA2):c.7051G>A (p.Ala2351Thr)
Other names:
p.A2351T:GCA>ACA; NP_000050.3:p.Ala2351Thr
HGVS:
  • NC_000013.11:g.32354904G>A
  • NG_012772.3:g.44425G>A
  • NM_000059.4:c.7051G>AMANE SELECT
  • NP_000050.2:p.Ala2351Thr
  • NP_000050.3:p.Ala2351Thr
  • LRG_293t1:c.7051G>A
  • LRG_293:g.44425G>A
  • LRG_293p1:p.Ala2351Thr
  • NC_000013.10:g.32929041G>A
  • NM_000059.3:c.7051G>A
  • NM_000059.4:c.7051G>A
  • U43746.1:n.7279G>A
  • p.A2351T
Protein change:
A2351T
Links:
dbSNP: rs80358930
NCBI 1000 Genomes Browser:
rs80358930
Molecular consequence:
  • NM_000059.4:c.7051G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000600732Quest Diagnostics Nichols Institute San Juan Capistrano
criteria provided, single submitter

(Quest Diagnostics criteria)
likely benign
(Sep 23, 2024)
unknownclinical testing

PubMed (19)
[See all records that cite these PMIDs]

SCV001467863Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Uncertain significance
(Dec 4, 2020)
germlineclinical testing

PubMed (7)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines.

Dietlein F, Eschner W.

Hum Mol Genet. 2014 Mar 15;23(6):1527-37. doi: 10.1093/hmg/ddt539. Epub 2013 Oct 26.

PubMed [citation]
PMID:
24163242

Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations.

Martelotto LG, Ng CK, De Filippo MR, Zhang Y, Piscuoglio S, Lim RS, Shen R, Norton L, Reis-Filho JS, Weigelt B.

Genome Biol. 2014 Oct 28;15(10):484. doi: 10.1186/s13059-014-0484-1.

PubMed [citation]
PMID:
25348012
PMCID:
PMC4232638
See all PubMed Citations (19)

Details of each submission

From Quest Diagnostics Nichols Institute San Juan Capistrano, SCV000600732.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (19)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV001467863.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (7)

Description

Variant summary: BRCA2 c.7051G>A (p.Ala2351Thr) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 6.7e-05 in 298156 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in BRCA2 causing Hereditary Breast and Ovarian Cancer Syndrome (6.7e-05 vs 0.00075), allowing no conclusion about variant significance. c.7051G>A has been reported in the literature in individuals affected with breast or ovarian cancer (example: Akbari_2011, Lee_2008, Momozawa_2018, Park_2020) as well as in controls (Momozawa_2018). These reports however, do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer Syndrome. Co-occurrences with other pathogenic variants have been reported in UMD and NHGRI BIC databases (BRCA2 c.1723A>T, p.Lys575X; BRCA1 c.2411_2412delAG, p.Gln804Leufs), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance (n=7) or likely benign (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Mar 16, 2025